- Home
- EHI vs DERM Comparison
EHI vs DERM Comparison
Compare EHI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EHI | DERM |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.6M | 210.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EHI | DERM |
|---|---|---|
| Price | $6.43 | $8.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | 44.5K | ★ 128.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 11.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $59,399,000.00 |
| Revenue This Year | N/A | $17.48 |
| Revenue Next Year | N/A | $55.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.82 |
| 52 Week Low | $6.00 | $3.54 |
| 52 Week High | $7.75 | $9.40 |
Technical Indicators
Market Signals| Indicator | EHI | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 57.77 | 53.99 |
| Support Level | $6.37 | $7.15 |
| Resistance Level | $6.44 | $8.40 |
| Average True Range (ATR) | 0.05 | 0.41 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 65.38 | 72.03 |
Price Performance
Historical ComparisonAbout EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.